Bitter melon peptide effects on blood sugar in people with prediabetes
Official title: Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides
Run by Chung Shan Medical University · NCT07504029 · Data updated 2026-11-12
This 12-week test will see if taking bitter melon (Momordica charantia) peptide capsules three times daily before meals can improve blood sugar control in adults with prediabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 65 Years |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Chung Shan Medical University Academic / other |
| Locations | 1 site (Taichung) |
| Status | Recruiting |
| Started | March 13, 2026 |
| Main results expected | July 31, 2026 |
| Study ends | July 31, 2026 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT07504029 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 30–65 with prediabetes (fasting glucose 100–125 mg/dL, HbA1c 5.7–6.4%, or 2-hour OGTT 140–199 mg/dL), BMI 24–35 kg/m², stable lifestyle habits, and willingness to take capsules three times daily are ideal candidates.
✕Probably not a fit
People with established type 2 diabetes, those taking antidiabetic drugs or other medications that affect blood glucose, or those outside the specified BMI or age ranges are unlikely to benefit from or qualify for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a 12-week, single-arm, open-label trial enrolling about 12 adults aged 30–65 with prediabetes to receive BmpP® bitter melon peptide capsules three times daily before meals. Participants will have fasting blood glucose, postprandial glucose responses, and HbA1c measured at baseline and during follow-up to track glycemic changes. The trial excludes people with diagnosed type 2 diabetes, those on antidiabetic medications, or those using supplements/medications that affect glucose. Findings will provide preliminary human data on whether this specific bitter melon peptide formulation influences short-term glycemic markers.
Why it matters
Potential benefit: If successful, the supplement could offer a simple oral approach to help lower fasting and postprandial glucose and potentially delay progression to type 2 diabetes.
How similar studies have gone: Animal studies and small human trials of bitter melon extracts have suggested possible glucose-lowering effects, but human evidence is limited and results have been mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 30-65 years, both male and female. * Participants meeting any of the following criteria for prediabetes: 1. Fasting blood glucose 100-125 mg/dL 2. HbA1c 5.7-6.4% 3. Previous clinical records indicating 2-hour OGTT glucose levels of 140-199 mg/dL * Body mass index (BMI) between 24-35 kg/m², with waist circumference recorded (men ≥90 cm; women ≥80 cm). * Stable lifestyle (including diet, physical activity, and sleep habits) during the past three months. * No use of blood glucose-regulating supplements prior to or during the study. * Willingness to comply with study procedures and complete all required assessments. * Provision of written informed consent. Exclusion Criteria: * Diagnosis of type 2 diabetes mellitus (HbA1c ≥6.5% or physician diagnosis). * Current use of antidiabetic medications (e.g., metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin). * Use of medications that may affect blood glucose levels, such as corticosteroids, antipsychotic drugs, or unstable thyroid medications. * Presence of severe hepatic, renal, cardiovascular diseases, active cancer, or gastrointestinal malabsorption disorders. * Pregnant or breastfeeding women, or those planning to become pregnant. * Body weight change exceeding ±5% within the past three months, or currently following a weight-loss program or special diet. * History of alcohol abuse or substance misuse. * Individuals engaged in night shift or rotating shift work. * Known allergy to any component of the study product. * Participation in another clinical trial within the past 1 month, or antibiotic use within the past 8 weeks (if gut microbiota analysis is involved). * Individuals who are students currently taught by Associate Professor You-Cheng Shen or Dr. Jing-Bin Lin, or laboratory staff, assistants, or employees with a supervisory or subordinate relationship with the investigators.
Where it's running
-
Chung Shan Medical University
Taichung, Taiwan Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.